About this trial
This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
cervical cancer, endometrial cancer, vulvar cancer, using indocyanine green, sentinel lymph node dissection
Disqualifiers
None
Trial population
Women who have endometrial or cervical or vulvar cancer
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Sentinel lymph node detection success rate associated with optimized indocyanine green (ICG) dosage and storage conditions.
Secondary outcomes
Impact of optimizing indocyanine green (ICG) dosage and storage conditions on total procedural cost.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.